← Patent-cliff monitor small molecule RADICAVA ORS EDARAVONE
Loss of exclusivity November 2041 latest FDA-listed patent expiry
Company Shionogi → See this company's full patent-cliff portfolio Drug detail Brand name RADICAVA ORS Active ingredient EDARAVONE Strength 105MG/5ML Dosage form SUSPENSION Route ORAL Modality Small molecule FDA approval May 2022 Marketing status RX
Listed patents Patent Expires Type 12194025 November 2041 use U-4111 12569469 November 2041 use U-4111 12478611 November 2041 use U-4111 12527769 November 2041 use U-4111 12310946 November 2041 use U-4111 11241416 November 2039 product 11957660 November 2039 product 11826352 November 2039 product 11478450 November 2039 use U-3468 10987341 November 2039 product 12285409 November 2039 product 12599586 November 2039 product
Regulatory exclusivity Code Expires ODE-144 May 2029
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.